GelSana Therapeutics
PrivateLast Round
Grant
Jul 14, 2025
Total Funding Raised
$7.9M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
GelSana Therapeutics operates in Healthcare & Life Sciences and is based in Aurora, Colorado. Its latest recorded funding round was a Grant round in July 2025.
GelSana Therapeutics is a biomaterials company developing novel hydrogel wound dressings designed to reduce inflammation and provide sustained drug delivery for chronic wounds.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Advanced Materials, Biotechnology
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GelSana Therapeutics Comparables
Compare GelSana Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BIOHEAL Therapeutics | 86% | |
| Gel4Med | 86% | |
| BioMimir Inc. | 83% |
For institutional investors. Book with your work email.
GelSana Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jul 14, 2025 | ||||
| Accelerator | Jun 5, 2025 | ||||
| Grant | Sep 5, 2024 | ||||
| Seed | Feb 19, 2024 | ||||
| Seed Round | Nov 20, 2023 | ||||
Grant | Nov 16, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
GelSana Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Arthritis and Musculoskeletal and Skin Diseases | Grant |
| MedTech Innovator | Accelerator |
| NIH RADx | Grant |
| Advanced Industries Accelerator Program | Grant |
| National Institute of Diabetes and Digestive and Kidney Diseases | Grant |
| Innosphere Ventures | Pre Seed |
| National Institute of Diabetes and Digestive and Kidney Diseases | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 1, 2026
Open roles increased to 2, 2.5x the trailing average.
- Jul 13, 2026
Open roles increased from 0 to 2, representing 25% of headcount.
For institutional investors. Book with your work email.
GelSana Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about GelSana Therapeutics's valuation, stock price, and market status.
Is GelSana Therapeutics a public or private company?
GelSana Therapeutics is a private company.
What is the current stock price of GelSana Therapeutics?
GelSana Therapeutics is a private company, so its shares have no public market price. Caplight tracks GelSana Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is GelSana Therapeutics worth (valuation)?
Valuation information for GelSana Therapeutics is not publicly available.
Can I buy GelSana Therapeutics stock?
GelSana Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was GelSana Therapeutics's last funding round?
GelSana Therapeutics's most recent funding round was Grant on July 14, 2025.
Who are the main investors in GelSana Therapeutics?
Key investors in GelSana Therapeutics include Innosphere Ventures, Innosphere Ventures.
Will GelSana Therapeutics IPO soon?
No public IPO plans have been announced for GelSana Therapeutics.
How can I track GelSana Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in GelSana Therapeutics's shares on secondary markets.